周一，UBS分析师Danielle Antalffy更新了Baxter International（NYSE:BAX）的财务展望，将公司目标价从此前的32.50美元上调至35.00美元。尽管作出这一调整，但该机构维持对这家医疗保健公司股票的"中性"评级。目前，该公司股价为35.08美元，市值为179亿美元。根据 InvestingPro ...

Baxter International Inc (BAX) reports robust earnings growth and outlines strategic priorities for 2025 despite facing operational challenges.

BAX reported fourth-quarter 2024 adjusted earnings per share (EPS) of 58 cents, which beat the Zacks Consensus Estimate of 52 cents by 11.5%. The bottom line declined 10.8% from the year-ago quarter’s ...

Baxter International ended 2024 on a positive note, overcoming challenges posed by Hurricane Helene and delivering better-than-expected Q4 results. The success of the Novum IQ infusion pump ...

So I'll say, we're very happy with the launch of Novum IQ and where we are. The teams are doing a great job driving this new platform. If you recall, Baxter placed a pretty big bet to internally ...

Following the completion of a massive restructuring plan, the medical equipment giant projects 4% to 5% sales growth this year.

Baxter reported Q4 adjusted EPS of $0.58, beating the $0.52 consensus and its own guidance of $0.50-$0.53. Baxter forecasts 2025 sales growth of 5%-6% and adjusted EPS of $2.45-$2.55, with Q1 2025 ...

Baxter calculates forward-looking non-GAAP financial measures based on forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2024, and provided its ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2024, and provided its ...